Pfizer's novel glaucoma candidate goes to trial
Pfizer has initiated the first in a series of planned clinical trials for PF-03187207, a new experimental medicine for the treatment of glaucoma.
Pfizer has initiated the first in a series of planned clinical trials for PF-03187207, a new experimental medicine for the treatment of glaucoma.
The Phase II, dose-finding study, will compare the safety and efficacy of PF-03187207 to latanoprost over a 28-day period. The randomized, double-masked study is expected to enrol 150 subjects with primary open angle glaucoma or ocular hypertension in one or both eyes.
PF-03187207 is the lead development compound generated under the August 2004 collaboration agreement between NicOx and Pfizer, which focuses on the research and development of nitric oxide-donating prostaglandin F2-alpha analogues for the treatment of glaucoma.
The initiation of the clinical trial follows the granting of an Investigational New Drug (IND) approval by the FDA, which in turn results in a €1 million milestone payment from Pfizer to NicOx.
